Hepatitis C Drugs Save Lives, but Sick Prisoners Aren’t Getting Them
April 26, 2018
Crohn’s patient says don’t give up
April 26, 2018
Show all

Multiple Sclerosis Drug: Treatment for Secondary Progressive

Can a new treatment slow progression of secondary progressive multiple sclerosis?

Is a breakthrough treatment for secondary progressive multiple sclerosis (SPMS) finally on the horizon?

It’s still too early to answer that question, but in a randomized, double-blind, placebo-controlled study, a new Novartis drug called siponimod (BAF132) was able to delay progression of the disease in people with SPMS, many of whom had already reached a stage of advanced disability.

The study, funded by Novartis, included 1,651 participants from 31 countries. The results were recently published in the peer-reviewed journal The Lancet.

After three months of use, siponimod was able to slow down the disease’s effects by 21 percent and reduced the risk of six-month disease progression by 26 percent.

Participants who took a daily oral dose of siponimod also lost less brain volume, had fewer brain lesions, and reduced their number of annual relapses by 55 percent. However, siponimod didn’t improve how well the participants could walk.

The results of this study show that siponimod “can delay disability progression in typical established SPMS patients, where other approaches tested so far have been unsuccessful,” Dr. Ludwig Kappos, a professor at University Hospital of Basel in Switzerland and the principal study investigator, said in a statement. “These data are all the more impressive when considering that the majority of patients already had advanced disability when starting treatment.”

Read on: Multiple Sclerosis Drug: Treatment for Secondary Progressive

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.